Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant

Aung M. Tun; Yucai Wang; Aasiya Matin; David J. Inwards; Thomas M. Habermann; Ivana Micallef; Patrick B. Johnston; Luis Porrata; Jonas Paludo; Jose Villasboas Bisneto; Allison Rosenthal; Han W. Tun; James R. Cerhan; Thomas E. Witzig; Grzegorz S. Nowakowski; Stephen M. Ansell

doi:10.1097/HS9.0000000000000869

Back

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant

Journal article

Open access

Peer reviewed

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant

Aung M. Tun, Yucai Wang, Aasiya Matin, David J. Inwards, Thomas M. Habermann, Ivana Micallef, Patrick B. Johnston, Luis Porrata, Jonas Paludo, Jose Villasboas Bisneto, …

HemaSphere, Vol.7(4), e869

04/04/2023

DOI: 10.1097/HS9.0000000000000869

PMCID: PMC10079336

PMID: 37034004

Files and links (1)

url

https://doi.org/10.1097/HS9.0000000000000869View

Published (Version of record) Open Access

Abstract

Immune checkpoint inhibitors (ICIs) and brentuximab vedotin (BV) are novel agents for classic Hodgkin lymphoma, including relapse after autologous stem cell transplant (ASCT). However, their impact on survival post-ASCT relapse, in comparison with conventional therapy, is less known due to the lack of randomized controlled trials. Clinical characteristics and outcomes of 115 patients with relapse (or progression) after ASCT are studied. After a median follow-up of 8.59 years from post-ASCT relapse, the median progression-free survival (PFS) and overall survival (OS) were 0.91 and 5.07 years, respectively. Median lines of therapy after post-ASCT relapse was 2 (range, 1–12). The median PFS was not reached (NR) versus 1.11 versus 0.50 versus 0.85 versus 0.78 years ( P = 0.006) and OS was NR versus 7.60 versus 3.08 versus 3.51 versus 3.17 years ( P = 0.28) in patients first treated with ICIs versus BV versus investigational agents versus chemotherapy versus radiation therapy (RT). First-line treatment with novel agents (ie, ICIs and BV) was associated with superior outcomes compared with investigational agents and chemotherapy/RT with a median PFS of 1.65 versus 0.50 versus 0.79 years ( P = 0.003) and a median OS of 7.60 versus 3.08 versus 3.32 years ( P = 0.08). Regardless of lines of therapy, the treatment with ICIs had the most favorable outcome with a median PFS and OS of 3.98 and NR years, respectively. Allogeneic stem cell transplant (allo-SCT) was done in 23 patients (20%), and the median post-allo-SCT PFS and OS were 1.31 and 2.35 years, respectively. In conclusion, survival following post-ASCT relapse improves significantly when patients receive novel agents.

Details

Title: Subtitle: Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant
Creators: Aung M. Tun - University of Kansas
Yucai Wang - Mayo Clinic
Aasiya Matin - Mayo Clinic
David J. Inwards - Mayo Clinic
Thomas M. Habermann - Mayo Clinic
Ivana Micallef - Mayo Clinic
Patrick B. Johnston - Mayo Clinic
Luis Porrata - Mayo Clinic
Jonas Paludo - Mayo Clinic
Jose Villasboas Bisneto - Division of Hematology, Mayo Clinic, Rochester, MN, USA
Allison Rosenthal - Mayo Clinic in Arizona
Han W. Tun - Mayo Clinic in Florida
James R. Cerhan - Mayo Clinic
Thomas E. Witzig - Mayo Clinic
Grzegorz S. Nowakowski - Mayo Clinic
Stephen M. Ansell - Mayo Clinic
Resource Type: Journal article
Publication Details: HemaSphere, Vol.7(4), e869
DOI: 10.1097/HS9.0000000000000869
PMID: 37034004
PMCID: PMC10079336
NLM abbreviation: Hemasphere
ISSN: 2572-9241
eISSN: 2572-9241
Publisher: Lippincott Williams & Wilkins
Language: English
Date published: 04/04/2023
Academic Unit: Epidemiology
Record Identifier: 9984386255902771

Metrics

8 Record Views

2 Times Cited - Web of Science